Prognostic Value of NT-proBNP in Predicting Adverse In-hospital Outcomes among Patients of STEMI getting Thrombolytic therapy without Clinical Manifestation of Heart Failure

Dutta, Bornali; Mohibullah, Akm; Karmoker, Kajal Kumar; Siddique, Khandaker Ayesha; Chowdhury, Shantanu; Kundu, Samir Kumar; Rahman, Zillur; Roy, Dipankar

doi:10.3329/cardio.v10i1.34355

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most extensively researched heart failure biomarkers are natriuretic peptides. The ventricles respond to stress by producing B type natriuretic peptide (BNP) and its physiologically inactive component NT-ProBNP 10 .…”

Section: Introductionmentioning

confidence: 99%

Established and Emerging Biomarker in Chronic Heart Failure

Islam,

Khan,

Hossain

et al. 2023

Bangladesh Heart J

View full text Add to dashboard Cite

Background: More than one million hospital admissions each year are due to heart failure as the major diagnosis. One in six patients over 65 who visit a primary care facility complaining of dyspnea with exertion has undiagnosed HF. By far, the most thoroughly investigated, extensively used, and acknowledged biomarkers for heart failure are natriuretic peptides. B type natriuretic peptide (BNP) and its biologically inactive fragment N-terminal pro B-type natriuretic peptide (NT-ProBNP), which are both primarily released by the ventricles in response to stretching, have been suggested to be useful for determining the prognosis or disease severity of chronic heart failure in earlier studies. Uric acid levels rise in CHF primarily due to increased production and occasionally due to decreased excretion or both. Elevated uric acid levels are a sign of developing heart failure and cardiac dysfunction. Numerous studies have demonstrated a connection between morbidity and death in CHF and elevated serum uric acid levels2. Objective: To find out the relationship between on admission serum uric acid level with established prognostic factors and Biomarkers such as different classes of NYHA, LVEF, NT-PROBNP, and their prognostic significance. Methods: From April 2018 to March 2019, this study was carried out at the National Heart Foundation Hospital and Research Institute's Department of Cardiology. After considering the inclusion and exclusion criteria, 148 patients with chronic heart failure who had admission serum uric acid measurement and telephone follow-up within 30 days were included. The study patients were divided into two groups based on Serum uric acid level Group I (SUA in men<7mg/dl) (SUA in women <6mg/dl), Group II (SUA in men ≥7mg/dl), (SUA in women ≥6mg/dl) Baseline characteristics, left ventricular ejection fraction (LVEF) were then compared between the two groups. Results: On 148 patients, the level of serum uric acid was assessed, and follow-up was done, patients with chronic heart failure were shown to have significantly higher levels of hyperuricemia, and there was a strong association between the severity of the rise in serum uric acid (SUA) and the severity of the heart failure. Elevated blood uric acid levels and ejection fraction have an antagonistic relationship. The severity of heart failure can be predicted by hyperuricemia, as evidenced by the association between patients with elevated blood UA levels and a worse New York Heart Association (NYHA) functional class. Higher uric acid levels in patients were linked to negative outcomes and a poor prognosis. Conclusion: As with NT Pro BNP or other well-established prognostic indicators, lower uric acid levels upon admission can be utilized to predict the prognosis of CHF patients. Bangladesh Heart Journal 2023; 38(2): 135-142

show abstract

Section: Introductionmentioning

confidence: 99%